Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 Sw Sam Jackson Park Rd
Mail Code L586, Mnp 3208
Portland, OR 97239Phone+1 503-494-6594
Summary
- Dr. Stephen Chui, MD is an oncologist in Portland, Oregon. He is currently licensed to practice medicine in Oregon. He is an Assistant Professor at Oregon Health and Science University School.
Education & Training
Duke University School of MedicineClass of 1996
Certifications & Licensure
OR State Medical License 2006 - 2025
Publications & Presentations
PubMed
- 7 citationsPARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast c...Rebecca Kristeleit, Alexandra Leary, Ana Oaknin, Andres Redondo, Angela George
British Journal of Cancer. 2024-09-01 - 9 citationsPatient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer.Carlos H Barrios, Shigehira Saji, Nadia Harbeck, Hong Zhang, Kyung H Jung
NPJ Breast Cancer. 2022-09-19 - 192 citationsAtezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 StudyLeisha A. Emens, Luciana Molinero, Sherene Loi, Hope S. Rugo, Andreas Schneeweiss
Journal of the National Cancer Institute. 2021-08-02
Press Mentions
Panel Tells FDA to Keep Atezolizumab Approval in TNBCApril 28th, 2021- FDA Panel Questions Roche's Tecentriq-Abraxane Combo in Breast Cancer, but Votes to Keep Approval in Place for NowApril 27th, 2021
